The efficacy and safety of BOTOX for the treatment of primary axillary hyperhidrosis were evaluated in two randomized, multi center, double-blind, placebo-controlled studies. Study 1 included adult patients with persistent primary axillary hyperhidrosis who scored 3 or 4 on a Hyperhidrosis Disease Severity Scale (HDSS) and who produced at least 50 mg of sweat in each axilla at res t over 5 minutes. HDSS is a 4-point scale with 1 = “underarm sweating is never noticeable and never interferes with my daily activities”; to 4 = “underarm sweating is intolerable and always interferes with my daily activities”. A total of 322 patients were randomized in a 1:1:1 ratio to treatment in both axillae with either 50 Units of BOTOX, 75 Units of BOTOX, or placebo. Patients were evaluated at 4-week intervals. Patients who responded to the first injection were re-injected when they reported a re-increase in HDSS score to 3 or 4 and produced at least 50 mg sweat in each axilla by gravimetric measurement, but no sooner than 8 we eks after the initial injection.
Since then, several randomized control trials have shown botulinum toxin type A to improve headache symptoms and quality of life when used prophylactically for patients with chronic migraine who exhibit headache characteristics consistent with: pressure perceived from outside source, shorter total duration of chronic migraines (<30 years), "detoxification" of patients with coexisting chronic daily headache due to medication overuse, and no current history of other preventive headache medications.
After Hoffman’s husband was diagnosed with Parkinson’s at 55, his health insurance decided to stop paying for the drug he had taken successfully unless he tried cheaper alternatives. She appealed on behalf of her husband and was eventually able to get approval for the drug, which would have cost them $8,000 a year otherwise. “I felt terrible and I had to fight and it took a long time,” Hoffman tells The Verge. “It caused a lot of anxiety and a lot of these patients don’t have a law professor wife to fight for them.”
I’ve been getting injections for migraine and cervical dystonia for a couple of years. Thank GAWD for Medicaid to cover it. I went 2 days ago for my 12 week appt. The relief was instantaneous. I’ve been under an immense amount of stress due to losing my only child 5 months ago. I’m still alive and virtually headache free. Botulism…who knew?! But…THANK YOU♡
As part of the settlement, Allergan agreed to plead guilty to one criminal misdemeanor misbranding charge and pay $375 million. The company acknowledged that its marketing of Botox led to off-label uses of the drug. Allergan also agreed to pay $225 million to resolve civil charges alleging that the marketing of Botox had caused doctors to file false reimbursement claims, though Allergan denied wrongdoing. The company said in a statement that the settlement was in the best interest of its stockholders because it avoided litigation costs and "permits us to focus our time and resources on ... developing new treatments."
Ptosis generally occurs from injecting the frontalis incorrectly. The worst mistake is for the injector to move the procerus and corrugator injection points higher, where they will place more onabotulinumtoxinA into the frontalis. It is important to examine patients to determine their preexisting conditions prior to treatment administration. In particular, patients should be examined for pre-existing eyelid ptosis or pseudoptosis. With pseudoptosis, the lid strength is normal, but soft tissue covers part of the upper lid. With lid ptosis, the lid strength is weak. For both lid ptosis and pseudoptosis, patients will have frontalis compensatory activity, resulting in upgoing eyebrows (reverse Babinski sign). With brow ptosis, the frontalis is weak, and the eyebrow is depressed downward leading to tissue resting on the upper lid. To avoid this, the frontalis should be injected in the upper third of the forehead. The corrugator muscle attaches to bone at the medial end of the superciliary arch. The muscle fibers travel laterally and upward inserting into the skin in the middle of the supraorbital margin. The corrugator muscle is partially blended with the orbicularis oculi and occipitofrontalis. The supraorbital and supratrochlear nerves pass through the corrugator muscle. The corrugator muscle acts to pull the eyebrows downward and medially, which causes vertical wrinkle lines in the skin between the brows.
It will not affect the nerves that cause sensation, or make you feel numb. When it is used correctly, it can lift the brow to give an appealing and sincere look. "But if too much is injected in the danger zone—the horizontal lines in the forehead—you can look Spocked, as in Spock from Star Trek," says Jean Carruthers, a Vancouver eye surgeon who, with her husband, Alastair, coauthored the first paper on the cosmetic benefits of Botox in 1989. That's why it's important to be treated by an experienced doctor who can judge the size of your muscles and how much Botox you will need.
Jump up ^ Mangera A, Andersson KE, Apostolidis A, Chapple C, Dasgupta P, Giannantoni A, Gravas S, Madersbacher S (October 2011). "Contemporary management of lower urinary tract disease with botulinum toxin A: a systematic review of botox (onabotulinumtoxinA) and dysport (abobotulinumtoxinA)". European Urology. 60 (4): 784–95. doi:10.1016/j.eururo.2011.07.001. PMID 21782318.
Khalaf Bushara and David Park were the first to demonstrate a nonmuscular use of BTX-A while treating patients with hemifacial spasm in England in 1993, showing that botulinum toxin injections inhibit sweating, and so are useful in treating hyperhidrosis (excessive sweating). BTX-A has since been approved for the treatment of severe primary axillary hyperhidrosis (excessive underarm sweating of unknown cause), which cannot be managed by topical agents.
Two years later, Allergan bought Oculinum for $9 million and changed the drug's name to Botox. At the time, Allergan was primarily an ocular-care company that sold products like contact-lens cleaners and prescription solutions for dry eyes, bringing in about $500 million in annual sales. Allergan says it saw Botox as a drug for a niche population: it's estimated that 4% of people in the U.S. have crossed eyes, for which the drug was initially approved, and Allergan made about $13 million in sales from the drug by the end of 1991.
Activewear & Athletic ShoesMen's Activewear,Men's Athletic Shoes,Wo...23823 CyclingBikes,Clothing & Footwear,Parts & Access...714 Exercise & FitnessBalance & Recovery,Books & Magazines,Car...5017 Fan ShopMemorabilia,MLB,NASCAR,NBA,NCAA,NFL,NHL...4619 Golf ProductsGolf Accessories,Golf Bags and Carts,Gol...362 OutdoorsAction Sports,Boats & Water Sports,Campi...10483